China News Service, June 13th, a comprehensive report, recently, the Argentine Ministry of Health approved the emergency use of the new crown vaccine of China Cansino Biotech Co., Ltd. in the country to promote a large-scale vaccination plan.
According to a Reuters report on the 12th, the Argentine Ministry of Health said that the government and China's Cansino Biotech Co., Ltd. are making progress in their negotiations to purchase 5.4 million doses of vaccine.
Argentine Minister of Health, Bissotti, said on social media that this is "good news" for Argentina, "this allows us to go one step further and continue to advance the mass vaccination plan."
Data map: The streets of Buenos Aires, Argentina.
According to previous reports, in 2020, China's Cansino Bio-New Coronary Vaccine has launched a Phase III clinical trial in Argentina.
According to the report published by the health agency that conducted the test in Argentina, the storage condition of the vaccine is 2-8 degrees Celsius, which is very conducive to storage and transportation. No volunteers participating in the test have reported adverse reactions.
In February 2021, Argentina formally approved the emergency use of the new crown vaccine developed by China National Pharmaceutical Group in the country.
On the advice of the Argentine Drug Administration, the Ministry of Health also decided to include the Chinese vaccine in the country's new crown vaccination plan.
At present, the new crown vaccines that people can get in Argentina include the Chinese National Medicine vaccine, the Russian "Satellite-V" vaccine, and the AstraZeneca vaccine.
So far, at least 12.6 million people have received one dose of vaccine and 3.2 million people have received two doses of vaccine.
As the supply of vaccines has accelerated, the rate of vaccination has also continued to increase in recent months.
Reuters statistics show that so far, nearly 85,000 people have died from the new crown virus in Argentina and 4.1 million people have been infected.